HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection
© Basu et al.; licensee BioMed Central Ltd. 2012
Received: 30 May 2012
Accepted: 3 September 2012
Published: 20 September 2012
The potential role of antibodies in protection against intra-subtype HIV-1 superinfection remains to be understood. We compared the early neutralizing antibody (NAb) responses in three individuals, who were superinfected within one year of primary infection, to ten matched non-superinfected controls from a Zambian cohort of subtype C transmission cases. Sequence analysis of single genome amplified full-length envs from a previous study showed limited diversification in the individuals who became superinfected with the same HIV-1 subtype within year one post-seroconversion. We hypothesized that this reflected a blunted NAb response, which may have made these individuals more susceptible to superinfection.
Neutralization assays showed that autologous plasma NAb responses to the earliest, and in some cases transmitted/founder, virus were delayed and had low to undetectable titers in all three superinfected individuals prior to superinfection. In contrast, NAbs with a median IC50 titer of 1896 were detected as early as three months post-seroconversion in non-superinfected controls. Early plasma NAbs in all subjects showed limited but variable levels of heterologous neutralization breadth. Superinfected individuals also exhibited a trend toward lower levels of gp120- and V1V2-specific IgG binding antibodies but higher gp120-specific plasma IgA binding antibodies.
These data suggest that the lack of development of IgG antibodies, as reflected in autologous NAbs as well as gp120 and V1V2 binding antibodies to the primary infection virus, combined with potentially competing, non-protective IgA antibodies, may increase susceptibility to superinfection in the context of settings where a single HIV-1 subtype predominates.
KeywordsHIV-1 superinfection Subtype C Neutralizing antibodies HIV-1 transmission HIV-1 dual infection
To develop a cross-protective HIV-1 vaccine that provides immunological breadth against multiple strains, a comprehensive understanding of the immunologic and virologic interactions that occur during HIV-1 superinfection in clinically relevant populations is critical. HIV-1 superinfection refers to re-infection with a heterologous HIV-1 variant in an HIV-infected individual, who has had the opportunity to mount an immune response to the primary infection . Elucidating immunological factors that may prevent superinfection (despite exposure to virus) will inform our understanding of possible correlates of protection from de novo infection, as well as what factors may contribute towards a successful vaccine-induced immune response.
Non-human primate studies have shown that neutralizing antibodies (NAbs) and passive transfer of broadly cross-reactive monoclonal antibodies can confer protection against simian-human immunodeficiency virus (SHIV) infection [2–7]. Results of the RV144 vaccine trial have also supported that specific humoral responses, including higher levels of V1V2-binding IgG antibodies, may have contributed to protection from primary HIV-1 infection in uninfected vaccinees, and that higher anti-Env plasma IgA levels may have contributed towards risk of primary HIV-1 infection in vaccinees [8, 9]. Another approach to address the potential contribution of antibodies to protection from primary HIV-1 infection is to evaluate whether they decrease susceptibility to superinfection. Specifically, antibody responses in individuals who become superinfected versus those who are similarly exposed to exogenous virus but remain singly-infected can be evaluated for differences that may confer protection. NAb responses in the context of superinfection have been studied in subtype A [10, 11] and B [12, 13] HIV-1 infection, in addition to settings where multiple clades and recombinant species are common [10, 14]. However, to date, there is no clear resolution of whether NAbs could play a role in modulating susceptibility to superinfection or whether trends observed in such studies were context-dependent.
Studies of a commercial sex worker (CSW) cohort in Mombasa, Kenya have shown HIV-1 intra- and inter-clade superinfections to occur during both early and chronic infection [10, 11, 15], with no significant difference in heterologous neutralization breadth or potency against a wide panel of cross-clade pseudoviruses in superinfected individuals versus non-superinfected matched controls prior to superinfection . In contrast, intrasubtype B superinfections in an MSM cohort in San Diego have been shown to occur primarily during the first year of infection, with lower baseline NAb breadth to two lab-adapted strains and autologous viruses isolated from pre-superinfection plasma . Other subtype B studies have also shown, through mathematical modeling, a 21-fold reduction in the rate of superinfection after the first year of infection , consistent with some change in susceptibility. However, despite the fact that most new seroconversions in adults occur in heterosexual discordant couples  in subtype C endemic areas, the dynamics of early humoral responses in the context of superinfection in this cohort type have not been thoroughly examined.
We previously reported, from an HIV-1 discordant couple cohort in Lusaka, Zambia [17, 18], a longitudinal study of 22 newly infected individuals, where three superinfection cases were identified (13.6%). HIV-1 superinfection was initially identified using a combination of screening methods with final confirmation by sequencing of single-genome amplified env genes . In each case, superinfection was by a virus from a non-spousal partner during the first year of infection. In all cases, the superinfecting variant predominated and extensive recombination between superinfecting and initial variants occurred after the superinfection event. The finding that superinfections were commonly seen during early infection from outside partners implicated potential roles for sexual risk behavior  and early immune responses in modulating superinfection outcomes in this cohort. We have therefore investigated early antibody responses in these three intrasubtype C superinfected individuals and 10 of the 19 non-superinfected individuals from the same Zambian cohort of heterosexual couples.
These studies show that autologous plasma NAb titers to the early/founder viruses were low to undetectable in all three superinfected individuals prior to superinfection, whereas the majority of non-superinfected controls mounted early and strong autologous responses to the early/founder Env as early as three months post-seroconversion. Similarly, gp120 and V1V2-specific IgG antibody titers were higher in matched controls while gp120-specific plasma IgA titers were higher in two of three superinfected individuals, suggesting that reduced IgG and increased IgA humoral immune responses may influence the risk of superinfection in this subtype C cohort.
Limited Envelope (Env) diversification in the initially infecting virus prior to superinfection
In a previous study of superinfection within a subset of 22 newly infected individuals from the Zambia-Emory HIV Research Project (ZEHRP) discordant couple cohort , we identified three individuals who were superinfected from non-spousal partners within the first year of infection (detected 3–10 months post-seroconversion) with subtype C superinfecting variants.
Neutralization of early/founder viruses during early infection
Seroconverters from ZEHRP cohort evaluated for longitudinal autologous neutralization of initial variants
Last Seronegative Date
First Sample Date
Estimated days from infectiona
Setpoint Viral loadc
Estimated timing of SId
Viral load at SIe
Sex with Condomf
Sex without Condomf
Initial Virus Envh
Interestingly, IC50 titers in ZM211F and ZM282M, in which superinfection was detected at 9 and 10-months post-seroconversion, were very low (150 and <100, respectively) until the time point at which superinfection was detected (dashed line, Figure 2; asterisk, Figure 3), suggesting that infection with a distinct secondary variant may have elicited an immunological boost. In ZM247F, in which we detected superinfection at 3-months and an early predominance of the superinfecting variant , we could not detect titers of neutralizing antibodies greater than 100 to a founder variant even at 12 months (Figure 3); it was not until 15-months post-seroconversion, when evidence for re-emergence of the founder virus was observed , that neutralizing antibodies to the founder became measurable (IC50 of 1092; Additional file 1: Figure S2A).
Cross-neutralization of superinfecting viruses during early infection
To investigate further possible reasons for susceptibility to superinfection, we determined whether pre-superinfection plasma was capable of cross-neutralizing pseudoviruses carrying Env glycoproteins isolated from the time at which superinfection was first detected. No evidence for cross-neutralization of the superinfecting variants by autologous pre-superinfection plasma existed for any of the three cases (Figure 4B). However, these superinfecting variants were neutralized by pooled subtype C plasma with IC50s of 210–572, suggesting they are not inherently neutralization resistant (Additional file 1: Figure S3).
In the case of early superinfection in ZM247F, although neutralization of the founder Env was not observed until after the first year of infection (Additional file 1: Figure S2A), we did observe preferential neutralization of the superinfecting variant with titers increasing from 6–12 months after superinfection was detected (Additional file 1: Figure S2B). This likely reflects the predominance of the superinfecting virus from 3–12 months post-seroconversion .
Heterologous neutralization breadth potential prior to superinfection
To evaluate whether superinfected individuals also lacked cross-neutralizing antibody breadth, we determined the ability of pre-superinfection plasma (as compared to contemporaneous plasma from controls) from early infection to neutralize a subtype C reference panel of 12 pseudoviruses. This panel included envelopes with tier 1 (“easiest” to neutralize) and tier 2 (more difficult to neutralize) sensitivities [27, 28].
Analysis of gp120 and V1V2-loop binding antibody levels prior to superinfection
In this study, we have shown that three intrasubtype C superinfected individuals, in whom superinfection was detected within the first year of infection, have low to undetectable titers of autologous NAbs to their early/founder Env prior to superinfection and as late as 8-months post-seroconversion. This is in sharp contrast to ten matched non-superinfected controls similarly evaluated for neutralization of early/founder variants over the first year of infection, of which a majority mounted very potent neutralizing activities. This occurred as early as three-months post-seroconversion, when the median IC50 was 1896. Despite the small size of this study, the differences in autologous NAb titers were significantly different between the two groups (p = 0.039), and suggest that slower development of a humoral immune response increased susceptibility to intra-subtype superinfection in this cohort.
This result is consistent with a previous study of a subtype B MSM cohort, where low titers of autologous and heterologous NAbs were observed in the three superinfected individuals relative to matched non-superinfected controls . However in this same study, autologous pre-superinfection Envs were tested for neutralization only cross-sectionally against contemporaneous pre-superinfection and post-superinfection plasma, and heterologous breadth assays were performed against only two lab-adapted subtype B strains. Moreover, there was no evaluation of cross-neutralization of the superinfecting virus using plasma prior to superinfection . Nevertheless, there is a common observation that superinfection occurred during the first year of infection, and was associated with low autologous neutralizing antibody responses . These results are consistent with the hypothesis that higher susceptibility to superinfection during early infection may be, in part, due to diminished early humoral responses.
A different conclusion was reached from a study of superinfection in HIV-1 infected commercial sex workers in Mombasa, Kenya . There it was shown that while NAb breadth and potency were lower in superinfected individuals than in matched controls after approximately one year of infection, no difference in these parameters occurred immediately prior to superinfection (between 0.72-5 years post-infection) . In 4/6 cases identified in that study, superinfection occurred at or after two years of the initial infection, potentially allowing for development of stronger, yet still not protective, NAb responses . Thus in this multiple HIV-1 subtype sex worker cohort, NAb did not appear to provide any protection from superinfection. While the authors did not investigate autologous NAb responses to transmitted/founder Env glycoproteins in the study, responses to initial variants cloned from the time of superinfection detection and early Envs from within the first year of infection were evaluated .
To evaluate cross-neutralization breadth prior to superinfection, we evaluated the potential of pre-superinfection plasma to neutralize not only superinfecting variants, isolated at the time superinfection was detected, but also a subtype C reference panel of pseudoviruses. We found that pre-superinfection plasma was unable to neutralize superinfecting variants and had limited ability to cross-neutralize a panel of variants prior to superinfection, with a range of 0–7 (of 12) variants neutralized at very low IC50s (20–70) amongst all three superinfected cases. Heterologous breadth in non-superinfected control plasma samples was similarly limited, though some individuals did have greater breadth but not potency. These data are consistent with previous studies, which showed that early autologous NAbs in subtype C infection are monotypic with limited cross-neutralization potential [22, 23, 26, 31, 32]. Furthermore, it has been demonstrated that significant cross-neutralizing antibody breadth is unlikely to occur prior to chronic infection [33, 34].
Heterologous neutralizing antibody breadth did not necessarily correlate with strength or effectiveness of autologous NAb responses. Although some non-superinfected individuals clearly mount strong autologous responses, they may exhibit limited neutralizing breadth by primarily targeting single or nonconserved epitopes [22, 23, 25, 26, 31, 32, 35, 36]. In contrast, others with relatively low-titer autologous responses may in fact have wider breadth to multiple epitopes (or different epitopes), none of which confers a particularly effective neutralizing antibody response to the established infecting variant. Thus, this study suggests that, in the context of intrasubtype superinfections, either the ability to potently neutralize autologous virus or to target multiple epitopes could provide protection against superinfection. However, in the absence of both of these humoral responses, individuals may be predisposed towards superinfection.
Based on the data suggesting early deficits in NAb responses in superinfected individuals, but with little evidence for broadly neutralizing antibodies in the matched controls, we investigated whether levels of non-neutralizing antibodies also differed in the two groups prior to superinfection. We observed that superinfected individuals trended towards having lower levels of gp120-specific IgG antibodies prior to superinfection compared to controls, although this comparison did not achieve statistical significance (p = 0.115).
Similarly, we observed no reactivity to either consensus clade C or caseA2clB (clade B) V1V2-loop fusion proteins [8, 30] in plasma from superinfected individuals prior to superinfection. By contrast in 3/10 non-superinfected matched controls, we observed reactivity to both proteins during the first 6 months, and in 6/10 controls reactivity was seen against the consensus C protein during the first year of infection. Higher levels of IgG V1V2-loop binding antibodies have been correlated with protection from primary HIV-1 infection in vaccinees that remained uninfected in the RV144 trial [8, 9], and the data presented here are consistent with the concept that these antibodies may contribute toward protection in individuals that remained only singly-infected.
In the RV144 trial, levels of IgA antibodies capable of binding to gp120 were directly correlated with the risk of infection [8, 9]. It is of interest, therefore, that two of the three superinfected individuals showed the highest anti-gp120 plasma IgA levels amongst all study participants, while only two of the ten matched controls demonstrated positive IgA binding titers. One superinfected individual, ZM211F, showed no evidence of anti-gp120 IgA reactivity. However, this is consistent with the low overall HIV-1 specific humoral responses observed, including the lowest levels of V1V2-loop and gp120-specific IgG binding antibodies prior to superinfection. We have also found a statistically significant difference in anti-gp120 plasma IgA levels with respect to sexual exposure and potential HIV-1 acquisition risk, in that individuals either with superinfection (as a result of outside partnerships) or self-reported outside partnerships (in non-superinfected individuals) had significantly higher anti-gp120 plasma IgA responses (p = 0.005), as compared to non-superinfected controls without self-reported outside partnerships. This data corroborates those drawn from the RV144 trial that high plasma IgA levels may be a surrogate of HIV-1 exposure or a potential correlate of risk in the context of primary HIV-1 infection  and superinfection. We have yet to evaluate the mechanism by which these differences in plasma IgA levels may affect susceptibility to infection, however it has been suggested that high levels of IgA may interfere with other potentially protective antibody-mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC) . Non-neutralizing IgG antibodies could play a major role in increased mucosal barrier protection, sequestering the virus at the epithelial surface and in female genital tract mucus and contributing to Fc receptor-mediated antiviral activity [6, 37, 38]. Thus a diminished non-neutralizing IgG antibody response, compounded by potentially interfering IgA antibodies, could lead to reduced mucosal protection and higher susceptibility to superinfection. Future studies will elucidate whether non-neutralizing antibody-mediated antiviral activities contribute to protection from superinfection.
Our previous study demonstrated three intrasubtype C superinfections during the first year of infection, with no evidence of superinfection beyond year one in 19 individuals, despite longitudinal follow-up for more than three years . This observation suggested that the risk of superinfection may be highest during the first year of infection, as has been predicted by mathematical modeling in a subtype B cohort . Here we evaluated the potential of the humoral immune response in natural infection to protect against superinfection. Autologous NAb responses were markedly delayed and lower in magnitude in superinfected individuals prior to superinfection detection (p = 0.039). Because of the strain-specific nature of early autologous NAb, this difference in titers may be a surrogate marker for a potential immunological deficit in protective antibodies or another factor contributing to effective humoral responses. Nevertheless, if confirmed in a larger ongoing study, these data provide support for the feasibility of inducing a protective immune response via an HIV-1 vaccine, in regions where subtype diversity is limited. It will be critical to understand the nature of vaccine-induced humoral responses and to what degree these antibodies can protect from de novo infection.
Heterosexual cohabiting couples in serodiscordant relationships were followed by the Zambia-Emory HIV Research Project (ZEHRP) in Lusaka, Zambia. ZEHRP provides couples’ voluntary counseling and testing as well as condom provision, general health care, and family planning counseling to participating couples [18, 39]. These strategies have been shown to effectively reduce transmission rates between partners in participating countries . Couples are tested for HIV-positivity, as previously published [18, 39–41]. Seroconversion of the initially uninfected partner occurs approximately 7-8% per year, and the new seroconverter is subsequently followed quarterly, with annual follow-up for the chronic partner. Plasma is collected at each visit from study participants, with informed consent and under human subject protocols approved by both the University of Zambia Research Ethics Committee and the Emory University Institutional Review Board.
Epidemiological linkage was determined as previously published; unlinked transmission pairs, in which the negative partner in the serodiscordant couple became infected from an individual outside of the partnership, were identified . Twenty-two unlinked couples were chosen and screened for superinfection for up to 5.5 years of follow-up . Viral RNA was extracted from plasma samples at the time of seroconversion and longitudinally thereafter using the QiaAMP Viral Mini Extraction kit for phylogenetic evaluation of viral sequences. Identified superinfected individuals were matched to 10 selected non-superinfected controls from the study  based on 1) time from the last seronegative to the first antigen or antibody positive sample, 2) seroconversion viral load, 3) subtype of infection and 4) occurrence of seroconversions within the same five-year interval. When possible, superinfected controls were matched to non-superinfected controls that had self-reported extra-marital (outside) partnerships (ZM249M, ZM184F). Underreporting of sexual exposures is common in this Zambian cohort , and in this study, all initial infections were identified as being epidemiologically unlinked, implicating risk for outside partnerships despite lack of self-reported cases.
Superinfection detection and characterization
Superinfections were identified by a combination of screening methods including phylogenetic analysis of gp41 and p24 gag population sequences, heteroduplex mobility assays using gp41 amplicons, and degenerate base counting of population sequences . If individuals showed preliminary evidence of superinfection, longitudinal full-length env single genome amplification was performed using nested PCR [19, 29, 44, 45] in order to confirm the presence of superinfection by phylogenetic analysis . Sanger DNA sequencing was performed by the University of Alabama at Birmingham Center for AIDS Research (P30 A127767) DNA Sequencing Shared Facility using a 3730xl DNA Analyzer and BigDye Terminator v3.1 chemistry.
Sequences were assembled and evaluated using Sequencher 4.10 (Gene Codes Corporation, Ann Arbor, MI) and Geneious Pro 5.4.6 (Biomatters Ltd, Auckland, New Zealand). Sequence alignments and neighbor-joining phylogenetic trees were generated using the Tamura-Nei genetic distance model with the bootstrap resampling method. Superinfecting variant gp41 sequences consistently had greater than 11% pairwise distance from the initial founder virus . Single genome sequences of full-length envs were amplified from plasma samples from all superinfected individuals from the time of seroconversion and longitudinally for the first year. All envs were processed as described above for phylogenetic analysis. Highlighter plots (LANL HIV Sequence Database) were used to evaluate longitudinal evolution of full-length env sequences from the determined early/founder sequence (see below). These plots were generated using aligned nucleotide sequences of the initial infection sequences only; each colored hatch-mark represents a single nucleotide change from the early/founder env sequence (red = T, green = A, orange = G, light blue = C). For longitudinal pairwise distance analyses, we used codon-aligned sequences to generate seroconversion consensus sequences, then computed raw pairwise distances to this consensus for each sequence sampled using R (version 2.15.0) with the package ‘ape’ (version 3.0-3) [46, 47].
Amplification and cloning of full-length envgenes
Phusion HotStart II Hi-Fidelity DNA polymerase (Finnzymes, Thermo Scientific) was used to amplify an average of 10 single genome full-length env amplicons per subject from plasma by nested PCR, as described elsewhere . These amplicons were obtained from the time of seroconversion (Table 1, Additional file 1: Figure S1), and a sequence alignment was generated to establish the consensus from this time point. The amplicons whose sequences matched this consensus were typically representative of the founder virus envelope glycoproteins (Table 1, Additional file 1: Figure S1). Superinfecting virus amplicons were selected by comparing the chosen early/founder virus sequence against all env sequences at the time of superinfection detection and selecting the superinfecting env variant with the greatest pairwise distance from the early/founder virus env sequence . These env genes were then directionally cloned using the pcDNA 3.1 Directional TOPO/v-His expression plasmid (Invitrogen), as previously described [21, 22, 29]. All clones were tested for biological function, sequenced, and co-transfected with env-defective subtype B provirus SG3ΔEnv into 293 T cells using FuGENE HD (Roche) to generate envelope pseudoviruses carrying patient-derived env genes [21–24, 29]. Envelope pseudoviruses were harvested 48-hours post-transfection. JC53BL-13 (TZM-bl) cells were infected at five-fold serial dilutions of virus for 48 hours for viral titering, and infectious units were determined through β-galactosidase staining and counting positive infected blue foci, as previously described [21–24, 29].
Neutralization assays & calculation of IC50 titers
Neutralization assays using the indicator cell line JC53BL-13 (TZM-bl) were performed, as previously described [21–25, 29]. Briefly, two thousand infectious units of envelope pseudoviruses in 3.5% FBS DMEM with 40 μg/ml DEAE-Dextran were incubated with five-fold serial dilutions of heat-inactivated patient plasma. Normal human plasma (NHP) was used to maintain an overall 10% concentration of plasma [22, 25, 29]. The virus-plasma mixture was added to seeded JC53BL-13 cells (plated and cultured overnight at 37°C) and incubated at 37°C for 48 hours, as previously described [22–25, 29]. Cells were then lysed and luciferase was read for each well; luminescence was recorded accounting for background. Percent viral infectivity and correlating neutralization IC50 values (representing plasma dilution resulting in 50% viral infectivity) were determined using a linear-regression-least squares fit method, as described elsewhere [21–24, 29]. For example, if 50% viral infectivity was achieved with a 1:2000 plasma dilution, the reported IC50 would be 2000. Each plasma-Env combination was tested in duplicate in each experiment and IC50 values shown represent mean IC50 values from at least two independent experiments.
For studies of autologous plasma neutralization, plasma dilutions started at 1:100, while for heterologous breadth studies, we started at a 1:20 plasma dilution in order to increase sensitivity for low titers of cross-reactive neutralizing antibodies. For the autologous neutralization studies, we tested the first post-seroconversion plasma and all subsequent plasma samples available within approximately the first year of infection. Seroconversion plasma was not tested for neutralization, and was assumed to be at our limit of detection for these studies at an IC50 of 100.
Heterologous neutralizing breadth and potency scores
The Subtype C HIV-1 Reference Panel of Env Clones [27, 28] was obtained from NIH AIDS Reference and Reagent Program, and pre-superinfection plasma in superinfected individuals (and contemporaneous samples from non-superinfected controls) was evaluated for heterologous breadth to the 12-pseudovirus panel. After generating viral infectivity curves, neutralization IC50 values were calculated for each plasma-virus combination. Each combination was tested in duplicate, and IC50 values were averaged between the wells. Any IC50 values that were not reached at the lowest plasma dilution tested (1:20) were assigned an IC50 value of 10. Neutralization breadth scores were determined by adding the number of pseudoviruses in the panel neutralized at an IC50 greater than 20, while potency scores were determined by dividing the plasma-virus IC50 by the median IC50 per virus (against all plasma samples) and adding the scores for each plasma sample [10, 48]. All potency score values were rounded to the nearest integer. In one case (ZM249M), because plasma was tested against an autologous envelope clone in the panel, IC50 values from this plasma-Env combination were discarded from the calculations for breadth and potency scores.
gp120 binding ELISA
gp120 binding ELISAs were performed in triplicate as previously described . Briefly, 96-well ELISA plates were coated overnight with 100 μl (2 μg/ml) purified gp120 protein (GeneART) from the Zambian subtype C seroconverter ZM205F [23, 29] at 4°C. Plates were then washed six times with PBS-T (PBS containing 0.1% Tween-20) and blocked with 200 μl B3T (150 mM NaCl, 50 mM Tris–HCl, 1 mM EDTA, 3.3% FBS, 2% BSA, 0.07% Tween-20 in 500 ml ddH20) for 1 hour at 37°C in a CO2-free incubator. Plates were washed again, and 100 μl/well of five-fold serially diluted heat-inactivated plasma was incubated for 1 hour at 37°C. After washing six times with PBS-T, 100 μl of diluted secondary antibody (HRP goat anti-human IgG) was added to each well for 1 hour at 37°C. After a final wash six times with PBS-T, 100 μl of SureBlue TMB substrate solution (equilibrated to room temperature) was added to each well. Plates were incubated for 10 minutes at room temperature. In order to stop the reaction, 100 μl of 1 N H2SO4 was added/well, and plates were read at 450 nm absorbance with a Biotek Synergy plate reader and luminometer. Wells coated with gp120 protein alone were used as blank control wells and were subtracted from absorbance readings, as described below in the Statistical analysis methods section.
This protocol was also adapted to measure plasma IgA levels, with the following changes: Test plasma was depleted of IgG using the GE Healthcare Protein G HP/Ab Spin Trap and was subsequently serially diluted five-fold at a starting concentration of 1:25 in B3T blocking buffer. Results shown at 1:125 plasma dilution are representative of the trends observed across the serial dilution. The secondary antibody was changed to an HRP-conjugated goat anti-human IgA antibody (InvivoGen). This assay was performed in duplicate with normal human plasma (NHP), autologous (ZM205F) 31-month plasma and Subtype C pooled plasma controls. Wells coated with gp120 protein alone were similarly used as blank control wells and were subtracted from absorbance readings.
V1V2 binding ELISA
A standard ELISA protocol was used to evaluate the presence of V1V2-specific IgG binding antibodies in heat-inactivated patient plasma (diluted 1:500 in 2% BLOTTO). Plates were coated with MuLVgp70-caseA2clB V1V2  or MuLVgp70-conC V1V2 (consensus clade C) scaffolded proteins with MuLVgp70 carrier alone as a control. Positive absorbance was defined as absorbance greater than five times that of the uninfected normal human plasma control.
All statistical analyses compared responses between superinfected and non-superinfected groups. We performed the Wilcoxon rank sum test using the autologous neutralizing antibody IC50 titers obtained in the 5–8 month post-seroconversion time frame, which reflects the neutralizing antibody titers before superinfection. As subject ZM247F was superinfected at this time, for this subject alone we used the values obtained at 3 months post-seroconversion (which were equal to those obtained from 9- and 12-month plasma).
To evaluate differences in gp120-specific IgG binding antibody levels in pre-superinfection plasma in superinfected individuals and similar time points for controls, we evaluated gp120 binding ELISA data performed in triplicate. For each ELISA trial, we first found the baseline binding to purified gp120 protein – the lowest absorption value from the blank control wells. After adjusting for this baseline value, the experimental values were plotted, and the curve interpolated to find the titration corresponding to 50% of the highest binding absorption value of the curve. After all binding50 values were determined, we log-transformed the values for further analysis. A linear mixed effects model was used to determine whether the binding50 values were associated with superinfection status. Log-transformed binding50 values were used as the response variable, and the superinfection status was used as a predictor with fixed effect. The individual effects were modeled as random effects. We also calculated mean binding50 values for each test plasma and compared medians between superinfected and non-superinfected groups, using a Mann–Whitney test run in GraphPad Prism 5.0d. We similarly adjusted test plasma absorption values for background binding (as measured in the blank control wells) in the gp120-specific IgA ELISA, and compared median absorption values between groups amongst both trials using a Mann–Whitney test run in GraphPad Prism 5.0d.
We gratefully recognize all of the RZHRG (Rwanda Zambia HIV Research Group) and ZEHRP (Zambia-Emory HIV Research Project) staff and the participants who made this study possible. We would also like to acknowledge Dr. Jesus Salazar (University of Alabama Birmingham) for contributing the ZM247Fv1-fs env clone and Dr. Chavdar Krachmarov, Kathy Revesz and William J. Honnen (Public Health Research Institute at the University of Medicine and Dentistry of New Jersey) for P623 (MuLVgp70- caseA2clB V1V2), P621 (MuLV gp70 carrier control) and P2442 (MuLVgp70-conC V1V2) proteins. We obtained the Subtype C HIV-1 Reference Panel of Env Clones (cat # 11326) through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.
This research was supported by grants from the National Institutes of Health (R37 AI-51235 (EH); R01 AI-58706 (CAD); U01 AI-78410 (AP), R56 AI091514-01A1 (PTH)) and the International AIDS Vaccine Initiative (SA). A Fogarty AITRP grant FIC 2D43 TW001042 supported WK. The Virology Core at the Emory Center for AIDS Research supported viral load testing (P30 AI050409). CSK was supported by an NRSA Institutional Postdoctoral Training Grant (T32 AI-007470) and National Institutes of Health/National Center for Research Resources (KL2 RR-025009). This project was also funded in part by the National Center for Research Resources P51RR165 and is currently supported by the Office of Research Infrastructure Programs/OD P51OD11132.
Nucleotide sequences: GenBank SGA accession numbers for ZM247F: EU166821.1, EU166792.1, EU166799.1, EU166800.1, EU166802.1, EU166816.1, EU166819.1. GenBank accession numbers for longitudinal SGA from superinfected individuals : JX239263 -JX239437. GenBank accession numbers for full-length founder/early env SGA in this study: JX213352 - JX213473.
- Allen TM, Altfeld M: HIV-1 superinfection. J Allergy Clin Immunol. 2003, 112: 829-835. 10.1016/j.jaci.2003.08.037. quiz 836View ArticlePubMed
- Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR: Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med. 2009, 15: 951-954. 10.1038/nm.1974.PubMed CentralView ArticlePubMed
- Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR: Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5: e1000433-10.1371/journal.ppat.1000433.PubMed CentralView ArticlePubMed
- Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, et al: Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999, 73: 4009-4018.PubMed CentralPubMed
- Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG: Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000, 6: 207-210. 10.1038/72318.View ArticlePubMed
- McElrath MJ, Haynes BF: Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. 2010, 33: 542-554. 10.1016/j.immuni.2010.09.011.PubMed CentralView ArticlePubMed
- Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, Moore JP: Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med. 2003, 9: 343-346. 10.1038/nm833.View ArticlePubMed
- Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012, 366: 1275-1286. 10.1056/NEJMoa1113425.PubMed CentralView ArticlePubMed
- McMichael AJ, Haynes BF: Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol. 2012, 13: 423-427. 10.1038/ni.2264.PubMed CentralView ArticlePubMed
- Blish CA, Dogan OC, Derby NR, Nguyen MA, Chohan B, Richardson BA, Overbaugh J: Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol. 2008, 82: 12094-12103. 10.1128/JVI.01730-08.PubMed CentralView ArticlePubMed
- Piantadosi A, Chohan B, Chohan V, McClelland RS, Overbaugh J: Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog. 2007, 3: e177-10.1371/journal.ppat.0030177.PubMed CentralView ArticlePubMed
- Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, Montefiori DC, O'Connor DH, Davis BT, Lee PK, et al: HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature. 2002, 420: 434-439. 10.1038/nature01200.View ArticlePubMed
- Smith DM, Strain MC, Frost SD, Pillai SK, Wong JK, Wrin T, Liu Y, Petropolous CJ, Daar ES, Little SJ, Richman DD: Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology. 2006, 355: 1-5. 10.1016/j.virol.2006.08.009.View ArticlePubMed
- Powell RL, Kinge T, Nyambi PN: Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus. J Virol. 2010, 84: 9415-9426. 10.1128/JVI.02732-09.PubMed CentralView ArticlePubMed
- Cortez V, Odem-Davis K, McClelland RS, Jaoko W, Overbaugh J: HIV-1 Superinfection in Women Broadens and Strengthens the Neutralizing Antibody Response. PLoS Pathog. 2012, 8: e1002611-10.1371/journal.ppat.1002611.PubMed CentralView ArticlePubMed
- Bragg L, McConnell J, Leigler T, Bacchetti P, Spotts G, Hecht F, Grant R: HIV-1 superinfection surveillance in an acute infection cohort using pol sequences from resistance genotyping: 1996–2009. Abstract Conference on Retroviruses and Opportunistic Infections. 2010, , San Francisco, CA
- Dunkle KL, Stephenson R, Karita E, Chomba E, Kayitenkore K, Vwalika C, Greenberg L, Allen S: New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet. 2008, 371: 2183-2191. 10.1016/S0140-6736(08)60953-8.View ArticlePubMed
- Allen S, Karita E, Chomba E, Roth DL, Telfair J, Zulu I, Clark L, Kancheya N, Conkling M, Stephenson R, et al: Promotion of couples' voluntary counselling and testing for HIV through influential networks in two African capital cities. BMC Publ Health. 2007, 7: 349-10.1186/1471-2458-7-349.View Article
- Kraft CS, Basu D, Hawkins PA, Hraber PT, Chomba E, Mulenga J, Kilembe W, Khu NH, Derdeyn CA, Allen SA, et al: Timing and source of subtype-C HIV-1 superinfection in the newly infected partner of Zambian couples with disparate viruses. Retrovirology. 2012, 9: 22-10.1186/1742-4690-9-22.PubMed CentralView ArticlePubMed
- Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, et al: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol. 1999, 73: 10489-10502.PubMed CentralPubMed
- Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML, Kasolo F, Musonda R, Hahn BH, et al: Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 2004, 303: 2019-2022. 10.1126/science.1093137.View ArticlePubMed
- Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, Allen S, Hunter E, Hahn BH, Shaw GM, et al: Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol. 2006, 80: 5211-5218. 10.1128/JVI.00201-06.PubMed CentralView ArticlePubMed
- Lynch RM, Rong R, Boliar S, Sethi A, Li B, Mulenga J, Allen S, Robinson JE, Gnanakaran S, Derdeyn CA: The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol. 2011, 85: 905-915. 10.1128/JVI.02006-10.PubMed CentralView ArticlePubMed
- Lynch RM, Rong R, Li B, Shen T, Honnen W, Mulenga J, Allen S, Pinter A, Gnanakaran S, Derdeyn CA: Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection. Virology. 2010, 404: 59-70. 10.1016/j.virol.2010.04.010.PubMed CentralView ArticlePubMed
- Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, et al: Antibody neutralization and escape by HIV-1. Nature. 2003, 422: 307-312. 10.1038/nature01470.View ArticlePubMed
- Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, et al: Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol. 2007, 81: 6187-6196. 10.1128/JVI.00239-07.PubMed CentralView ArticlePubMed
- Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, et al: Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006, 80: 11776-11790. 10.1128/JVI.01730-06.PubMed CentralView ArticlePubMed
- Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, et al: Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010, 84: 1439-1452. 10.1128/JVI.02108-09.PubMed CentralView ArticlePubMed
- Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, et al: Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 2009, 5: e1000594-10.1371/journal.ppat.1000594.PubMed CentralView ArticlePubMed
- Pinter A, Honnen WJ, Kayman SC, Trochev O, Wu Z: Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine. 1998, 16: 1803-1811. 10.1016/S0264-410X(98)00182-0.View ArticlePubMed
- Moore PL, Gray ES, Morris L: Specificity of the autologous neutralizing antibody response. Curr Opin HIV AIDS. 2009, 4: 358-363. 10.1097/COH.0b013e32832ea7e8.PubMed CentralView ArticlePubMed
- Moore PL, Ranchobe N, Lambson BE, Gray ES, Cave E, Abrahams MR, Bandawe G, Mlisana K, Abdool Karim SS, Williamson C, Morris L: Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009, 5: e1000598-10.1371/journal.ppat.1000598.PubMed CentralView ArticlePubMed
- Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, Werner L, Mlisana K, Sibeko S, Williamson C, et al: The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011, 85: 4828-4840. 10.1128/JVI.00198-11.PubMed CentralView ArticlePubMed
- Stamatatos L, Morris L, Burton DR, Mascola JR: Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med. 2009, 15: 866-870.PubMed
- Frost SD, Wrin T, Smith DM, Kosakovsky Pond SL, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos CJ, et al: Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A. 2005, 102: 18514-18519. 10.1073/pnas.0504658102.PubMed CentralView ArticlePubMed
- Richman DD, Wrin T, Little SJ, Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003, 100: 4144-4149. 10.1073/pnas.0630530100.PubMed CentralView ArticlePubMed
- Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, et al: Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007, 449: 101-104. 10.1038/nature06106.View ArticlePubMed
- Hope TJ: Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Nat Med. 2011, 17: 1195-1197. 10.1038/nm.2528.View ArticlePubMed
- McKenna SL, Muyinda GK, Roth D, Mwali M, Ng'andu N, Myrick A, Luo C, Priddy FH, Hall VM, von Lieven AA, et al: Rapid HIV testing and counseling for voluntary testing centers in Africa. AIDS. 1997, 11 (Suppl 1): S103-110.PubMed
- Boeras DI, Luisi N, Karita E, McKinney S, Sharkey T, Keeling M, Chomba E, Kraft C, Wall K, Bizimana J, et al: Indeterminate and discrepant rapid HIV test results in couples' HIV testing and counselling centres in Africa. J Int AIDS Soc. 2011, 14: 18-10.1186/1758-2652-14-18.PubMed CentralView ArticlePubMed
- Kempf MC, Allen S, Zulu I, Kancheya N, Stephenson R, Brill I, Tichacek A, Haworth A, Chomba E: Enrollment and retention of HIV discordant couples in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2008, 47: 116-125. 10.1097/QAI.0b013e31815d2f3f.View ArticlePubMed
- Trask SA, Derdeyn CA, Fideli U, Chen Y, Meleth S, Kasolo F, Musonda R, Hunter E, Gao F, Allen S, Hahn BH: Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. J Virol. 2002, 76: 397-405. 10.1128/JVI.76.1.397-405.2002.PubMed CentralView ArticlePubMed
- Allen S, Meinzen-Derr L, Kautzman M, Zulu I, Trask S, Fideli U, Musonda R, Kasolo F, Gao F, Haworth A: Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS. 2003, 17: 733-740. 10.1097/00002030-200303280-00012.View ArticlePubMed
- Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, Manigart O, Mulenga J, Keele BF, Shaw GM, et al: Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 2009, 5: e1000274-10.1371/journal.ppat.1000274.PubMed CentralView ArticlePubMed
- Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA, Farmer P, Hunter E, Allen S, et al: Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol. 2008, 82: 3952-3970. 10.1128/JVI.02660-07.PubMed CentralView ArticlePubMed
- Paradis E: Analysis of Phylogenetics and Evolution with R, Second Edition. 2012, Springer, New York, 1-386.View Article
- Paradis E, Claude J, Strimmer K: APE: Analyses of Phylogenetics and Evolution in R language. Bioinformatics. 2004, 20: 289-290. 10.1093/bioinformatics/btg412.View ArticlePubMed
- Lynch JB, Nduati R, Blish CA, Richardson BA, Mabuka JM, Jalalian-Lechak Z, John-Stewart G, Overbaugh J: The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection. J Virol. 2011, 85: 5252-5261. 10.1128/JVI.02216-10.PubMed CentralView ArticlePubMed
- Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010, 329: 856-861. 10.1126/science.1187659.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.